A hallmark of drugs with the PD-1/PD-L1 axis is the induction of deep and durable antitumor responses that can translate into a survival benefit in patients with a variety of tumor histologies (Tumeh et al., 2014; Garon et al., 2015; Overman et al., 2018). Here, CD274 is linked to neoplasm.